Page last updated: 2024-11-05

methadyl acetate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Methadyl acetate is a synthetic opioid analgesic that is structurally similar to methadone. It is a long-acting medication that is used to treat opioid addiction. Methadyl acetate is administered orally, and it is metabolized in the liver. The effects of methadyl acetate include pain relief, sedation, and euphoria. Methadyl acetate is also associated with a number of side effects, including constipation, nausea, vomiting, and dizziness. Methadyl acetate is studied because it has the potential to be a more effective and safer treatment for opioid addiction than methadone. Methadyl acetate is also being investigated for its potential use in the treatment of chronic pain.'

Methadyl Acetate: A narcotic analgesic with a long onset and duration of action. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID10517
CHEMBL ID170179
CHEBI ID135491
SCHEMBL ID119911
MeSH IDM0013546

Synonyms (52)

Synonym
methadyl acetate [usan]
acetilmetadol
acetylmethadol [inn]
l59oc40kwj ,
unii-l59oc40kwj
acetylmethadolum
levomethadyl
4-(dimethylamino)-1-ethyl-2,2-diphenylpentyl acetate
methadyl acetate (usan)
acetylmethadol (inn)
D04973
509-74-0
methadyl acetate
DB01433
acetylmethadol
1-ethyl-4-dimethylamino-2,2-diphenylpentylacetat
(r,s)-4-dimethylamino-1-ethyl-2,2-diphenylpentyl acetat
3-acetoxy-6-dimethylamino-4,4-diphenylheptane
einecs 208-103-4
acetylmethadolum [inn-latin]
race-acetylmethadol
dea no. 9601
acemethadone
acetilmetadol [inn-spanish]
6-(dimethylamino)-4,4-diphenyl-3-heptanol acetate (ester)
benzeneethanol, beta-(2-(dimethylamino)propyl)-alpha-ethyl-beta-phenyl-, acetate (ester)
CHEBI:135491
[6-(dimethylamino)-4,4-diphenylheptan-3-yl] acetate
L000758
ids-na-004
nih-2953
acscn-9601
CHEMBL170179 ,
acetic acid 4-dimethylamino-1-ethyl-2,2-diphenyl-pentyl ester
acetic acid (1s,4s)-4-dimethylamino-1-ethyl-2,2-diphenyl-pentyl ester
bdbm50027391
SCHEMBL119911
benzeneethanol, .beta.-(2-(dimethylamino)propyl)-.alpha.-ethyl-.beta.-phenyl-, acetate (ester)
o-acetyl-6-dimethylamino-4,4-diphenyl-3-heptanol
methadyl acetate [mi]
levo-.alpha.-acetylmethadol
levomethadyl acetate hydrochloride (salt/mix)
4-(dimethylamino)-1-ethyl-2,2-diphenylpentyl acetate, (3s,6s)-(-)-
benzeneethanol, .beta.-((2s)-2-(dimethylamino)propyl)-.alpha.-ethyl-.beta.-phenyl-, acetate (ester), (.alpha.s)-
(-)-.alpha.-acetylmethadol
XBMIVRRWGCYBTQ-UHFFFAOYSA-N
benzeneethanol, .beta.-[2-(dimethylamino)propyl]-.alpha.-ethyl-.beta.-phenyl-, acetate (ester), [s-(r*,r*)]-
orlaam (salt/mix)
mk 790 (salt/mix)
l-.alpha.-acetylmethadol
DTXSID2023274
Q4673310

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Lofexidine significantly reduced opiate withdrawal symptoms without the adverse sedative and hypotensive effects that limit the safety and usefulness of clonidine."( Opiate withdrawal using lofexidine, a clonidine analogue with fewer side effects.
Geyer, G; Resnick, RB; Washton, AM, 1983
)
0.27
"08) for lower retention and a greater number of agonist adverse effects were observed in the high-dose group."( Induction with levomethadyl acetate: safety and efficacy.
Bigelow, GE; Eissenberg, T; Johnson, RE; Jones, HE; Stitzer, ML; Strain, EC; Walsh, SL, 1998
)
0.63
" Induction with higher LAAM doses can be safely achieved within 17 days, but may result in greater rates of patient dropout and opioid agonist adverse effects."( Induction with levomethadyl acetate: safety and efficacy.
Bigelow, GE; Eissenberg, T; Johnson, RE; Jones, HE; Stitzer, ML; Strain, EC; Walsh, SL, 1998
)
0.63
"The study estimated serious adverse event (SAE) rates among entrants to pharmacotherapies for opioid dependence, during treatment and after leaving treatment."( Serious adverse events in the Australian National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD).
Digiusto, E; Mattick, RP; O'Brien, S; Ritter, A; Shakeshaft, A, 2004
)
0.32

Pharmacokinetics

ExcerptReferenceRelevance
" This study examined the pharmacodynamic and pharmacokinetic profile of LAAM when given orally and intravenously to humans."( Intravenous and oral l-alpha-acetylmethadol: pharmacodynamics and pharmacokinetics in humans.
Bigelow, GE; Cone, EJ; Johnson, RE; Walsh, SL, 1998
)
0.3

Dosage Studied

ExcerptRelevanceReference
" Dinoracetylmethadol plasma levels remained relatively constant throughout the dosing interval."( Disposition of acetylmethadol in relation to pharmacologic action.
Inturrisi, CE; Kaiko, RF, 1975
)
0.25
" Cardiac output, heart rate, respiratory rate and minute volume were decreased below mean pre-drug control values after drug administration in the two higher dosage groups; cardiac output in both groups failed to return to pre-drug control levels."( Effect of 1-alpha-acetylmethadol (LAAM) on various physiological parameters in the conscious dog.
Catravas, JD; Davis, WM; Guinn, MM; Waters, IW, 1978
)
0.26
" The starting dose was identical to the previously established dose of methadone, but beginning with the second visit, dosage was flexible."( A cooperative clinical study of methadyl acetate. I. Three-times-a-week regimen.
Gillis, RD; Klett, CJ; Ling, W, 1978
)
0.54
" Dosage was fixed for the balance of the 40-week treatment period."( Methadyl acetate and methadone as maintenance treatments for heroin addicts. A veterans administration cooperative study.
Charuvastra, C; Kaim, SC; Klett, CJ; Ling, W, 1976
)
1.7
" A mean quantity equal to 28% of the administered dose was excreted in the urine of a 48-h dosing interval as acetylmethadol and metabolites."( Simultaneous determination of acetylmethadol and its active riotransformation products in human biofluids.
Chatterjie, N; Inturrisi, CE; Kaiko, RF, 1975
)
0.25
" Three times per week dosing of LAAM proved to be a safe and effective treatment agent for the majority of subjects."( Clinical experiences with 959 opioid-dependent patients treated with levo-alpha-acetylmethadol (LAAM).
Pumphrey, E; Rawson, RA; Seecof, R; Tennant, FS, 1986
)
0.27
"Monkeys receiving acetylmethadol thrice weekly were more active on dosing days, and less active on between-dose days, than while drug-free."( Variability in simian motor and social behavior with alternating-day acetylmethadol.
Crowley, TJ; Macdonald, MJ; Zerbe, G, 1985
)
0.27
" Patients randomly assigned to the gradual group (group G) began 4-mg/wk reduction the Monday of week 9 and reached zero dosage (placebo) the Monday of week 23; patients in the abrupt group (group A) continued to receive 50, 50, and 65 mg until the Monday of week 23, when their dosage was dropped to zero (placebo)."( Methadyl acetate (LAAM) in the treatment of heroin addicts. II. Double-blind comparison of gradual and abrupt detoxification.
Goldstein, A; Inturrisi, CE; Judson, BA, 1983
)
1.71
" These LAAM-induced changes demonstrated dose- and time-dependence within that dosage range producing mortality."( L-alpha-acetylmethadol-induced tissue alterations in mice.
Freeman, RW; Harbison, RD; James, RC, 1984
)
0.27
" Outcome measures included retention to the end of the dosing schedule, use of illicit drugs during treatment, subjective discomfort, satisfaction, staff ratings of global progress, and durability of change at a three-month follow-up."( Withdrawal from heroin in three or six weeks. Comparison of methadyl acetate and methadone.
Hargreaves, WA; Sorensen, JL; Weinberg, JA, 1982
)
0.51
" Drug accumulation occurred in some subjects, but within the study range, dosage was not related to maximum plasma levels nor to accumulation."( Plasma and urine disposition of 1-alpha-acetylmethadol and its principal metabolites in man.
Chinn, DM; Finkle, BS; Holmes, ED; Jennison, TA; Ling, W,
)
0.13
" They also preferred LAAM to methadone on nine of 15 criteria such as the dosage schedule, feeling 'normal', and reduction of craving for heroin."( A comparison of thrice weekly LAAM and daily methadone in employed heroin addicts.
Czertko, G; Freedman, RR, 1981
)
0.26
" Some specific clinical practices, such as provision of adequate dose levels and flexible dosing practices, appear to be associated with superior clinical response, but issues of staff and organizational attitude toward the new medication are probably the most important impediments to a more positive response."( A 3-year progress report on the implementation of LAAM in the United States.
Hasson, AL; Huber, AM; Ling, W; McCann, MJ; Rawson, RA, 1998
)
0.3
" This study compared induction with 3 different LAAM dosage levels."( Induction with levomethadyl acetate: safety and efficacy.
Bigelow, GE; Eissenberg, T; Johnson, RE; Jones, HE; Stitzer, ML; Strain, EC; Walsh, SL, 1998
)
0.63
" Comparisons of physiological and subjective measures collected in agonist exposure sessions indicate that LAAM is not less potent than methadone under acute dosing conditions."( Relative potency of levo-alpha-acetylmethadol and methadone in humans under acute dosing conditions.
Bigelow, GE; Buchhalter, AR; Eissenberg, T; Stitzer, ML; Walsh, SL, 1999
)
0.3
" Buprenorphene may be one alternative to methadone, however the optimum dosage pattern is as yet unknown."( [Review of scientific evidence on alternatives to methadone in the psychopharmacologic treatment of opiate dependence].
Aizpuru, A; Aizpurua, I; Iruín, A; Ruiz de Apodaka, J; Zapiraín, E,
)
0.13
" Therapeutic drug monitoring for methadone in plasma continues to be evaluated for use in establishing adequate dosing and detecting diversion, and new methods have been devised for measurement of the optical isomers of methadone in plasma."( Toxicologic aspects of heroin substitution treatment.
Cone, EJ; Preston, KL, 2002
)
0.31
"LAAM and methadone are both full mu opiate agonists and have been shown to reduce dependence on heroin when given continuously under supervised dosing conditions."( LAAM maintenance vs methadone maintenance for heroin dependence.
Clark, N; Dunlop, A; Gijsbers, A; Ling, W; Lintzeris, N; Ritter, A; Whelan, G, 2002
)
0.31
" After 6-8 weeks on LAAM, plasma concentrations of the norLAAM metabolite varied significantly by LAAM dosing day, plasma adrenocorticotropin (ACTH) concentrations were significantly increased compared to methadone, and two of the seven subjects remaining in LAAM treatment were free of illicit opioids and nonprescribed methadone."( The use of levo-alpha-acetylmethadol (LAAM) in methadone patients who have not achieved heroin abstinence.
Appel, P; Borg, L; Ho, A; Joseph, H; Kreek, MJ; Moody, D; Wells, A, 2002
)
0.31
" Dose-response functions for heroin, methadone, LAAM, three other isomers of acetylmethadol: alpha- d-acetylmethadol, beta- d-acetylmethadol, beta- l-acetylmethadol, and its precursor, beta- l-methadol were examined."( Heroin discriminative stimulus effects of methadone, LAAM and other isomers of acetylmethadol in rats.
Beardsley, PM; May, EL; Newman, JL; Vann, RE, 2002
)
0.31
" Methadone and LAAM dosing was supervised through local community pharmacies."( A randomized trial comparing levo-alpha acetylmethadol with methadone maintenance for patients in primary care settings in Australia.
Bammer, G; Clark, N; Kutin, JJ; Lintzeris, N; Panjari, M; Ritter, AJ, 2003
)
0.32
" There were two dosing errors."( A randomized trial comparing levo-alpha acetylmethadol with methadone maintenance for patients in primary care settings in Australia.
Bammer, G; Clark, N; Kutin, JJ; Lintzeris, N; Panjari, M; Ritter, AJ, 2003
)
0.32
" In comparison to (R)-methadone, plasma nor- and dinor-LAAM concentrations fluctuated little over the dosing interval."( Evaluation of levo-alpha-acetylmethdol (LAAM) as an alternative treatment for methadone maintenance patients who regularly experience withdrawal: a pharmacokinetic and pharmacodynamic analysis.
Bochner, F; Newcombe, DA; Somogyi, AA; White, JM, 2004
)
0.32
"LAAM is an effective medication for the treatment of opiate dependence with clinical advantages due not only to the reduction of opiate use but also to the alternate-day dosing schedule."( Levo-alpha-acetylmethadol (LAAM) versus methadone: treatment retention and opiate use.
Anglin, MD; Annon, J; Longshore, D; Rawson, RA, 2005
)
0.33
"7 g/70 kg of alcohol in two separate sessions, one 2-3 hours before opioid pharmacotherapy dosing and the other 1-2 hours after dosing."( Effect of opioid substitution therapy on alcohol metabolism.
Clark, NC; Dietze, P; Lenné, MG; Redman, JR, 2006
)
0.33
" Individually optimized flexible dosing was used for each group, with weekly possible doses of 255-391 mg of LAAM, 56-112 mg of BUP, and 420-700 mg of METH."( HIV risk behaviors during pharmacologic treatment for opioid dependence: a comparison of levomethadyl acetate [corrected] buprenorphine, and methadone.
Bigelow, GE; Brooner, RK; Johnson, RE; Lott, DC; Strain, EC, 2006
)
0.55
" In subjects whose dosage of levomethadyl or methadone remained fixed over at least 8 weeks, the QTc continued to increase progressively over time (P = ."( QT-interval effects of methadone, levomethadyl, and buprenorphine in a randomized trial.
Bigelow, GE; Haigney, MC; Johnson, RE; Nuzzo, PA; Wedam, EF, 2007
)
0.34
" It is not recommended to use a fixed equianalgesic formula for the dosage conversion from other opioids."( [Accidental levomethadone intoxication in a palliative patient].
Maier, C; Michel-Lauter, B; Schwarzer, A, 2012
)
0.38
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
diarylmethaneAny compound containing two aryl groups connected by a single C atom.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Methadyl Acetate Action Pathway3111

Research

Studies (363)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990235 (64.74)18.7374
1990's32 (8.82)18.2507
2000's86 (23.69)29.6817
2010's9 (2.48)24.3611
2020's1 (0.28)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 15.82

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index15.82 (24.57)
Research Supply Index6.18 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (15.82)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials74 (18.23%)5.53%
Reviews36 (8.87%)6.00%
Case Studies9 (2.22%)4.05%
Observational0 (0.00%)0.25%
Other287 (70.69%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Opioid Maintenance: Optimum Stabilization and Withdrawal [NCT00218127]Phase 2142 participants (Actual)Interventional2001-11-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]